M. Center, . Research, and . Treatment, Department of Transfusion Medicine, Infectious Diseases and Immunogenetics Section (IDIS) Clinical Center and Center for Human Immunology, issue.7 10

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466

K. Flaherty, I. Puzanov, K. Kim, A. Ribas, G. Mcarthur et al., Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-828, 2010.
DOI : 10.1056/NEJMoa1002011

J. Lane and S. Bertuzzi, Measuring the Results of Science Investments, Science, vol.331, issue.6018, pp.678-80, 2011.
DOI : 10.1126/science.1201865

C. Haqq, M. Nosrati, D. Sudilovsky, J. Crothers, D. Khodabakhsh et al., The gene expression signatures of melanoma progression, Proceedings of the National Academy of Sciences, vol.102, issue.17, pp.6092-6099, 2005.
DOI : 10.1073/pnas.0501564102

M. Kashani-sabet, J. Rangel, S. Torabian, M. Nosrati, J. Simko et al., A multi-marker assay to distinguish malignant melanomas from benign nevi, Proceedings of the National Academy of Sciences, vol.106, issue.15, pp.6268-72, 2009.
DOI : 10.1073/pnas.0901185106

J. Rangel, S. Torabian, L. Shaikh, M. Nosrati, F. Baehner et al., Prognostic Significance of Nuclear Receptor Coactivator-3 Overexpression in Primary Cutaneous Melanoma, Journal of Clinical Oncology, vol.24, issue.28, pp.4565-4574, 2006.
DOI : 10.1200/JCO.2006.07.3833

M. Kashani-sabet, S. Venna, J. Rangel, M. Nosrati, A. Sucker et al., A Multimarker Prognostic Assay for Primary Cutaneous Melanoma, Clinical Cancer Research, vol.15, issue.22, pp.6987-92, 2009.
DOI : 10.1158/1078-0432.CCR-09-1777

P. Filipazzi, R. Valenti, V. Huber, L. Pilla, P. Canese et al., Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor???Based Antitumor Vaccine, Journal of Clinical Oncology, vol.25, issue.18, pp.2546-53, 2007.
DOI : 10.1200/JCO.2006.08.5829

R. Critchley-thorne, N. Yan, S. Nacu, J. Weber, S. Holmes et al., Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma, PLoS Medicine, vol.19, issue.5, p.176, 2007.
DOI : 10.1371/journal.pmed.0040176.st002

R. Critchley-thorne, D. Simons, N. Yan, A. Miyahira, F. Dirbas et al., Impaired interferon signaling is a common immune defect in human cancer, Proceedings of the National Academy of Sciences, vol.106, issue.22, pp.9010-9015, 2009.
DOI : 10.1073/pnas.0901329106

A. Tarhini, J. Stuckert, S. Lee, C. Sander, and J. Kirkwood, Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694, Journal of Clinical Oncology, vol.27, issue.1, pp.38-44, 2009.
DOI : 10.1200/JCO.2008.17.1777

. Van-den-eynde and . Bj, T cell defined tumor antigens, Current Opinion in Immunology, vol.9, issue.5, pp.684-93, 1997.
DOI : 10.1016/S0952-7915(97)80050-7

M. Marchand, C. Punt, S. Aamdal, B. Escudier, W. Kruit et al., Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report, European Journal of Cancer, vol.39, issue.1, pp.70-77, 2003.
DOI : 10.1016/S0959-8049(02)00479-3

W. Kruit, S. Suciu, B. Dreno, V. Chiarion-sileni, L. Mortier et al., Immunization with the recombinant MAGE-A3 protein combined with Adjuvant Systems AS02B or AS15 in patients with metastatic melanoma: final results of a Phase II study of the EORTC Melanoma Group, pp.0-0001, 2009.

A. Spatz, B. Dreno, V. Chiarion-sileni, L. Mortier, C. Robert et al., MAGE-A3 Antigen-Specific Cancer Immunotherapy (ASCI) clinical activity in metastatic melanoma is associated with predictive biomarkers present in the tumor prior to immunization [abstract]. Canadian Melanoma Conference, 2010.

J. Vansteenkiste, M. Zielinski, A. Linder, J. Dahabreh, E. Esteban et al., Phase II randomized study of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non- Small Cell Lung Cancer (NSCLC): 44 month follow-up, humoral and cellular immune response data, p.148, 2008.

J. Louahed, F. Lehmann, F. Ulloa-montoya, O. Gruselle, B. Dizier et al., Abstract A37: Identification of a gene expression signature predictive of clinical activity following MAGE-A3 ASCI treatment, Molecular Cancer Therapeutics, vol.8, issue.Supplement 1, p.1, 2009.
DOI : 10.1158/1535-7163.TARG-09-A37

D. Schwartzentruber, D. Lawson, J. Richards, R. Conry, D. Miller et al., A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract], Proc Am Soc Clin Oncol, vol.27, p.18, 2009.

P. Ascierto, H. Streicher, and M. Sznol, Melanoma: A model for testing new agents in combination therapies, Journal of Translational Medicine, vol.8, issue.1, p.38, 2010.
DOI : 10.1186/1479-5876-8-38

F. Pagès, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-66, 2005.
DOI : 10.1056/NEJMoa051424

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006.
DOI : 10.1126/science.1129139

B. Mlecnik, M. Tosolini, A. Kirilovsky, A. Berger, G. Bindea et al., Histopathologicalbased prognostic factors of colorectal cancers are associated with the state of the local immune reaction, J Clin Oncol

J. Galon and W. Fridman, The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective, Cancer Research, vol.67, issue.5, pp.1883-1889, 2007.
DOI : 10.1158/0008-5472.CAN-06-4806

G. Bindea, B. Mlecnik, W. Fridman, F. Pagès, and J. Galon, Natural immunity to cancer in humans, Current Opinion in Immunology, vol.22, issue.2, pp.215-237, 2010.
DOI : 10.1016/j.coi.2010.02.006

B. Mlecnik, M. Tosolini, P. Charoentong, A. Kirilovsky, G. Bindea et al., Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer, Gastroenterology, vol.138, issue.4, pp.1429-1469, 2010.
DOI : 10.1053/j.gastro.2009.10.057

F. Pages, A. Kirilovsky, B. Mlecnik, M. Tosolini, G. Bindea et al., In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5944-51, 2009.
DOI : 10.1200/JCO.2008.19.6147

C. Clemente, M. Mihm, . Jr, R. Bufalino, S. Zurrida et al., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer, vol.49, issue.7, pp.1303-1313, 1996.
DOI : 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5

F. Pagès, J. Galon, M. Dieu-nosjean, E. Tartour, C. Sautès-fridman et al., Immune infiltration in human tumors: a prognostic factor that should not be ignored, Oncogene, vol.173, issue.8, pp.1093-102, 2010.
DOI : 10.1038/nrc1586

. Ascierto, Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010", Journal of Translational Medicine, vol.9, issue.1, p.32, 2010.
DOI : 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5

URL : https://hal.archives-ouvertes.fr/inserm-00834025